Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Shots: Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an…

ByRidhi RastogiJanuary 7, 2026

Know Your Investor: BVF Partners L.P. (September’24 Edition)

Shots: An equity hedge fund manager company, BVF Partners invests in small cap and early-stage biotechnology companies In 2023, BVF participated in five investment rounds and added 20 companies to its portfolio For a curated report on a specific investor or venture capital, reach out to us at connect@pharmashots.com Established in 1993 in San Francisco, California,…

ByPrince GiriSeptember 5, 2024

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Know Your Investor: BVF Partners L.P. (September’24 Edition)

PharmaShots’ Key Highlights of Fourth Quarter 2022

Contact US

FOLLOW US